Toggle Nav
Close
  • Menu
  • Setting

Zalcitabine

Catalog No.
B2223
Reverse transcriptase inhibitor
Grouped product items
SizePriceStock Qty
10mM (in 1mL DMSO)
$50.00
In stock
50mg
$45.00
In stock
100mg
$65.00
In stock

Tel: +1-832-696-8203

Email: [email protected]

Worldwide Distributors

Background

Zalcitabine is a nucleoside analog reverse transcriptase inhibitor (NRTI).

Chemical Properties

Physical AppearanceA solid
StorageStore at -20°C
M.Wt211.22
Cas No.7481-89-2
FormulaC9H13N3O3
Solubilityinsoluble in EtOH; ≥10.65 mg/mL in DMSO with gentle warming; ≥15.87 mg/mL in H2O with ultrasonic
Chemical Name4-amino-1-[(2R,5S)-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one
SDFDownload SDF
Canonical SMILESC1CC(OC1CO)N2C=CC(=NC2=O)N
Shipping ConditionShip with blue ice, or upon other requests.
General tipsFor obtaining a higher solubility, please warm the tube at 37°C and shake it in the ultrasonic bath for a while.

Protocol

Cell experiment:[1]

Cell lines

3201 (feline lymphoid) cells, 81C (sarcoma-positive, leukemia-negative feline lung fibroblast) cells, and primary feline bone marrow cells

Reaction Conditions

0 ~ 384 μM zalcitabine

Applications

Zalcitabine (5 ~ 10 μM) inhibited feline leukemia virus (FeLV) infection of feline lymphoid cells by greater than 80%, while 6.07 ~ 12.13 μM zalcitabine was required to similarly inhibit infection of feline fibroblasts. However, 43 ~ 384 μM zalcitabine was needed to inhibit FeLV infection of primary bone marrow cells by greater than 80%.

Animal experiment:[1]

Animal models

Cats challenged intravenously with FeLV 1 ~ 3 days after drug treatment began

Dosage form

22, 15, 10, and 5 mg/kg per h

Administered by continuous intravenous infusion for 28 days

Applications

Doses of 22 and 15 mg/kg per h were extremely toxic, causing death in 8 of 10 cats. The 10 mg/kg per h dose was slightly toxic, causing chronic progressive thrombocytopenia over the 28-day treatment period. Of 10 cats given 10 or 5 mg of zalcitabine per kg per h, only one was completely protected from FeLV antigenemia. However, conversion to positive FeLV antigenemia status was delayed by 2 ~ 7 weeks in seven of nine remaining animals.

Note

The technical data provided above is for reference only.

References:

1. Polas PJ, Swenson CL, Sams R, et al. In vitro and in vivo evidence that the antiviral activity of 2',3'-dideoxycytidine is target cell dependent in a feline retrovirus animal model. Antimicrobial Agents and Chemotherapy, 1990, 34(7): 1414-1421.

Quality Control